Novartis' Lutathera radioligand therapy may soon face first generic challenger

Novartis has built a sizable business delivering radioligand therapies, with Lutathera being a leading product.

A rival company is preparing to launch the first generic version, which could introduce competition into a market dominated by Novartis.

The entry of a generic could affect pricing and market share for Lutathera, prompting Novartis to consider strategies to protect its position.

The move signals a broader competitive shift in radioligand therapy, potentially accelerating innovation and cost pressures across the sector.